Volume 68 Received 11 November 2012 | ||||||||||
| ||||||||||
aDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla University and Nanotec-PSU Center of Excellence for Drug Delivery Systems, Hat-Yai, Songkhla 90112, Thailand, and bDepartment of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand
Correspondence e-mail: vimon.t@psu.ac.th
In the title compound, C20H20O4 {systematic name: 4-[(3R)-8,8-dimethyl-3,4-dihydro-2H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diol}, the hydropyran ring linked to the pendant benzene ring adopts an envelope conformation, with the methyne C atom forming the flap. In the crystal, the -OH group at the 3-position of the benzene ring forms an O-H
O hydrogen bond to a chromene O-atom acceptor, whereas the -OH group at the 1-position forms an O-H
interaction with a neighboring benzene ring. The O-H
O hydrogen bonds form [001] chains and the O-H
bonds cross-link the chains into (101) sheets. The absolute structure was assumed to be the same as that deduced from previous studies for the natural product.
For background to the pharmacological activity of the title compound, see: Fukai et al. (2000
); Messier & Grenier; (2011
); Thiyagarajan et al. (2011
); Ahn et al. (2012
); Choi (2005
). For the assignment of the absolute structure, see: Kim et al. (2009
).
|
|
| ||||||||||||||||||||||
Data collection: SMART (Bruker, 1998
); cell refinement: SAINT (Bruker, 2003
); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008
); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008
); molecular graphics: Mercury (Macrae et al., 2008
); software used to prepare material for publication: SHELXTL (Sheldrick, 2008
) and publCIF (Westrip, 2010
).
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: HB6989 ).
Financial support by the Nanotechnology Center (NANOTEC), NSTDA, Ministry of Science and Technology, Thailand, through Center of Excellence Network program is gratefully acknowledged.
Ahn, J., Lee, H., Jang, J., Kim, S. & Ha, T. (2012). Food Chem Toxicol. 51, 439-445.
Bruker (1998). SMART. Bruker AXS Inc., Madison, Wisconsin, USA.
Bruker (2003). SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
Choi, E. M. (2005). Biochem. Pharmacol. 70, 363-368.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Fukai, T., Sakagami, H., Toguchi, M., Takayama, F., Iwakura, I., Atsumi, T., Ueha, T., Nakashima, H. & Nomura, T. (2000). Anticancer Res. 20, 2525-2536.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Kim, M., Kim, S.-N., Kim, Y.-U. & Han, J. (2009). Bull. Kor. Chem. Soc. 30, 415-418. ![[ChemPort]](../../../../../../logos/chemportborder.gif)
Macrae, C. F., Bruno, I. J., Chisholm, J. A., Edgington, P. R., McCabe, P., Pidcock, E., Rodriguez-Monge, L., Taylor, R., van de Streek, J. & Wood, P. A. (2008). J. Appl. Cryst. 41, 466-470.
![[details]](../../../../../../j/graphics/details.gif)
Messier, C. & Grenier, D. (2011). Mycoses, 54, 801-806. ![[CrossRef]](../../../../../../logos/crossrefborder.gif)
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
![[details]](../../../../../../a/graphics/details.gif)
Thiyagarajan, P., Chandrasekaran, C. V., Deepak, H. B. & Agarwal, A. (2011). Inflammopharmacology, 19, 235-241.
![[PubMed]](../../../../../../logos/pubmedborder.gif)
Westrip, S. P. (2010). J. Appl. Cryst. 43, 920-925.
![[details]](../../../../../../j/graphics/details.gif)